Product: Tau Antibody
Catalog: AF6141
Description: Rabbit polyclonal antibody to Tau
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog, Chicken
Mol.Wt.: 50-80kDa; 79kD(Calculated).
Uniprot: P10636
RRID: AB_2835022

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%), Chicken(100%)
Tau Antibody detects endogenous levels of total Tau.
Cite Format: Affinity Biosciences Cat# AF6141, RRID:AB_2835022.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


AI413597; AW045860; DDPAC; FLJ31424; FTDP 17; G protein beta1/gamma2 subunit interacting factor 1; MAPT; MAPTL; MGC134287; MGC138549; MGC156663; Microtubule associated protein tau; Microtubule associated protein tau isoform 4; Microtubule-associated protein tau; MSTD; Mtapt; MTBT1; MTBT2; Neurofibrillary tangle protein; Paired helical filament tau; Paired helical filament-tau; PHF tau; PHF-tau; PPND; PPP1R103; Protein phosphatase 1, regulatory subunit 103; pTau; RNPTAU; TAU; TAU_HUMAN; Tauopathy and respiratory failure, included;



Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type.



Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P10636 As Substrate

Site PTM Type Enzyme
A2 Acetylation
Y18 Phosphorylation P06241 (FYN) , P43405 (SYK)
T39 Phosphorylation
S46 Phosphorylation
T50 Phosphorylation
S56 Phosphorylation
S61 Phosphorylation
S171 Phosphorylation
T173 Phosphorylation
S214 Phosphorylation O00141 (SGK1)
S232 Phosphorylation
S235 Phosphorylation Q00535 (CDK5)
S238 Phosphorylation
S255 Phosphorylation Q13131 (PRKAA1)
S355 Phosphorylation Q13131 (PRKAA1)
S369 Phosphorylation Q13627 (DYRK1A)
T386 Phosphorylation
S388 Phosphorylation
S396 Phosphorylation P49841 (GSK3B) , Q13131 (PRKAA1) , P48730 (CSNK1D)
S400 Phosphorylation P49841 (GSK3B)
S411 Phosphorylation
T449 Phosphorylation
S451 Phosphorylation
T466 Phosphorylation
T470 Phosphorylation
T492 Phosphorylation
T498 Phosphorylation P53779 (MAPK10) , P45983 (MAPK8) , P49841 (GSK3B) , Q00535 (CDK5) , P45984 (MAPK9)
S501 Phosphorylation
S502 Phosphorylation
S508 Phosphorylation
S512 Phosphorylation P49841 (GSK3B)
Y514 Phosphorylation
S515 Phosphorylation P49841 (GSK3B) , Q5TCY1 (TTBK1)
S516 Phosphorylation Q00535 (CDK5) , Q5TCY1 (TTBK1) , P45984 (MAPK9) , P53779 (MAPK10) , P49841 (GSK3B) , P45983 (MAPK8)
S519 Phosphorylation Q13627 (DYRK1A) , P53779 (MAPK10) , P45983 (MAPK8) , P48730 (CSNK1D) , Q5TCY1 (TTBK1) , Q00535 (CDK5) , P49841 (GSK3B) , P45984 (MAPK9) , P28482 (MAPK1)
T522 Phosphorylation P45983 (MAPK8) , P48730 (CSNK1D) , P49841 (GSK3B) , Q00535 (CDK5) , P28482 (MAPK1) , P53779 (MAPK10)
S525 O-Glycosylation
S525 Phosphorylation
S527 Phosphorylation
T529 Phosphorylation P45984 (MAPK9) , Q8IWQ3 (BRSK2) , P45983 (MAPK8) , P49841 (GSK3B) , Q8TDC3 (BRSK1) , Q13627 (DYRK1A) , P53779 (MAPK10) , Q92630 (DYRK2) , P57059 (SIK1) , Q00535 (CDK5)
S531 Phosphorylation P49841 (GSK3B) , P57059 (SIK1) , P17612 (PRKACA) , Q00535 (CDK5)
T534 Phosphorylation Q00535 (CDK5) , P53779 (MAPK10) , P49841 (GSK3B) , P45983 (MAPK8)
T537 Phosphorylation
T548 Phosphorylation P45984 (MAPK9) , Q9UQM7 (CAMK2A) , P17612 (PRKACA) , P49841 (GSK3B) , Q00535 (CDK5)
S552 Phosphorylation Q9UQM7 (CAMK2A) , Q00535 (CDK5)
S554 Phosphorylation
S555 O-Glycosylation
S555 Phosphorylation
S558 Phosphorylation
K571 Ubiquitination
S575 Phosphorylation
S579 Phosphorylation P57059 (SIK1) , Q9P0L2 (MARK1) , P17612 (PRKACA) , Q8TDC3 (BRSK1) , P49841 (GSK3B) , P49840 (GSK3A) , Q9UQM7 (CAMK2A) , O96017 (CHEK2) , Q8IWQ3 (BRSK2)
T580 Phosphorylation
S602 Phosphorylation
S610 Phosphorylation P57059 (SIK1)
K611 Methylation
S622 Phosphorylation P57059 (SIK1)
Y627 Phosphorylation
K628 Acetylation
K628 Ubiquitination
S633 Phosphorylation
T636 Phosphorylation
S637 Phosphorylation Q16512 (PKN1)
S641 Phosphorylation P49840 (GSK3A) , Q9P0L2 (MARK1) , P57059 (SIK1)
S669 Phosphorylation
K670 Ubiquitination
S673 Phosphorylation Q9P0L2 (MARK1) , P17612 (PRKACA) , P57059 (SIK1)
K686 Acetylation
K687 Acetylation
T690 Phosphorylation
T694 Phosphorylation
Y711 Phosphorylation
S713 Phosphorylation Q00535 (CDK5) , P49840 (GSK3A) , P45984 (MAPK9) , P45983 (MAPK8) , P53779 (MAPK10) , P49841 (GSK3B)
S717 O-Glycosylation
S717 Phosphorylation P49841 (GSK3B)
T720 Phosphorylation
S721 Phosphorylation P45984 (MAPK9) , P49841 (GSK3B) , Q00535 (CDK5) , P45983 (MAPK8) , Q13627 (DYRK1A) , P28482 (MAPK1) , P53779 (MAPK10) , P49840 (GSK3A) , P48730 (CSNK1D)
S726 Phosphorylation P17612 (PRKACA)
S729 Phosphorylation
S730 Phosphorylation
T731 Phosphorylation
S733 Phosphorylation
S739 Phosphorylation P53779 (MAPK10) , P45984 (MAPK9) , P45983 (MAPK8) , Q5TCY1 (TTBK1)
T744 Phosphorylation

Research Backgrounds


Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.


Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK1, CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1, MARK2, MARK3 or MARK4), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age. Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tau/MAP's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by GSK3B reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2 in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation on Ser-717. Dephosphorylated at several serine and threonine residues by the serine/threonine phosphatase PPP5C.

Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

O-glycosylated. O-GlcNAcylation content is around 8.2%. There is reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on Ser-717 decreases the phosphorylation on Ser-721 by about 41.5%.

Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.

Subcellular Location:

Cytoplasm>Cytosol. Cell membrane>Peripheral membrane protein>Cytoplasmic side. Cytoplasm>Cytoskeleton. Cell projection>Axon. Cell projection>Dendrite.
Note: Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

Subunit Structure:

Interacts with MARK1, MARK2, MARK3 AND MARK4. Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated. Interacts with FKBP4 (By similarity). Binds to CSNK1D. Interacts with SGK1. Interacts with EPM2A; the interaction dephosphorylates MAPT at Ser-396. Interacts with PIN1. Interacts with LRRK2.


The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.


1). Andrographolide Protects PC12 Cells Against β-Amyloid-Induced Autophagy-Associated Cell Death Through Activation of the Nrf2-Mediated p62 Signaling Pathway. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (PubMed: 30235892) [IF=5.6]

Application: WB    Species:    Sample: PC12 cells

Figure 9. |Effect of Nrf2 siRNA on p62, p21, and p-tau/tau protein expression levels in PC12 cells. (C,D) After transfection with 20 µM of Nrf2 siRNA, cells were then pre-treated with Andro (20 µM) for 1 h followed by stimulation with Aβ (10 µM) for an additional 24 h. Then, p62, p21, and p-tau/tau protein expression levels were evaluated by Western blot analysis. * p < 0.05 versus the blank control;# p < 0.05 versus Andro+Aβ1–42 group were considered statistically significant differences.

2). Cerebroprotein hydrolysate attenuates neurodegenerative changes in Alzheimer’s mice model via ferroptosis pathway. Frontiers in Pharmacology [IF=5.6]

3). Ginsenoside Rg1 attenuates LPS-induced cognitive impairments and neuroinflammation by inhibiting NOX2 and Ca2+–CN–NFAT1 signaling in mice. Journal of Functional Foods [IF=5.6]

Application: WB    Species: Mouse    Sample: brain tissue

Fig. 3. Effects of Rg1 on the expressions of MAP2, PSD95, Tau, p-Tau, Bax and Bcl-2 in brain tissue of LPS-exposed mice (immunoblot). (A) The bands and relative expression of MAP2 over control. (B) The bands and relative expression of p22phox over control. (C) The bands and relative expression of Tau over control. (D) The bands and relative expression of p-Tau/Tau over control. (E) The bands and relative expression of Bax over control. (F) The bands and relative expression of Bcl-2 over control. Results are expressed as the mean ± SD, n = 4. **P < 0.01 compared with control group; #P < 0.05, ##P < 0.01 compared with LPS group.

4). MiR-702-5p ameliorates diabetic encephalopathy in db/db mice by regulating 12/15-LOX. EXPERIMENTAL NEUROLOGY (PubMed: 36029808) [IF=5.3]

5). Hypothermia impairs glymphatic drainage in traumatic brain injury as assessed by dynamic contrast-enhanced MRI with intrathecal contrast. Frontiers in Neuroscience (PubMed: 36816105) [IF=4.3]

Application: WB    Species: Rat    Sample: brains

FIGURE 6 Cognitive function was evaluated with the novel-object recognition test (A) and the Barnes maze test (B). In both trials, TBI-HT and TBI-NT rats showed impaired cognitive performance compared with sham controls (*p < 0.05, TBIs vs. sham and TBI-HT vs. TBI-NT, n = 8–12 animals per group). Posttraumatic cognitive impairment was exacerbated in the hypothermic TBI rats compared with the normothermic TBI rats (**p < 0.05 TBI-HT vs. TBI-NT, n = 12 animals per group). (C) Western blot analysis shows obvious beta-amyloid and p-tau accumulation in rat brains 1 month after TBI and hypothermia. Quantitative analysis shows significantly increased β-amyloid (D) and p-tau (E) deposition in TBI-HT and TBI-NT rats compared with sham controls (Mean ± SD, one-way ANOVA with Bonferroni’s post-hoc test for multiple comparisons; n = 4–6 animals per group, n.s.: not significant). The correlation between p-tau and β-amyloid accumulation with glymphatic dysfunction and cognitive deficits is described in box plot graphs (F–H). Box plot graphs (F) show that the amyloid β and p-tau levels in the brains of sham control, TBI-NT, and TBI-HT rats were inversely linearly related to the reduced influx and efflux rate and linearly related to the increased clearance constant of high-molecular-weight contrast transported along with perivascular spaces (pineal and pituitary recess and periarterial space of the olfactory artery) in the four groups (r2 = 0.94, 0.92, 0.93 for amyloid β level and r2 = 0.90, 0.89, 0.91 for tau level and the influx rate, efflux rate and clearance constant, respectively, all p < 0.01, Spearman’s correlation test, n = 20). Scatter plot graphs (G,H) show that the amyloid β and p-tau levels in the brains of the four groups are linearly related to their increased mean escape time in the Barnes maze test (amyloid β: r2 = 0.96, p-tau: r2 = 0.95, p < 0.01, Spearman’s correlation test, n = 20) and inversely linearly related to their decreased discrimination index in the novel object recognition test (amyloid β: r2 = 0.97, p-tau: r2 = 0.94, p < 0.01, Spearman’s correlation test, n = 20).

6). Therapeutic Mechanism of Kai Xin San on Alzheimer’s Disease Based on Network Pharmacology and Experimental Validation. Chinese Journal of Integrative Medicine (PubMed: 36474082) [IF=2.9]

7). Stress causes cognitive impairment by affecting cholesterol efflux and reuptake leading to abnormalities in lipid metabolism of rats. Journal of integrative neuroscience (PubMed: 32259885)

Application: WB    Species: rat    Sample: hippocampus

Figure 4. |Tau protein phosphorylation and impairment of synaptic plasticity in CUMS rats. (A) The expression of p-Tau and Tau in control rats and CUMS rats in the sixth week and tenth week of the CUMS period.

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.